IP Library Granted Patent US 9,883,901
Granted Patent B2
US 9,883,901 · App. 14/674,539 · Granted Feb 6, 2018

Characterizing ablation lesions using optical coherence tomography (OCT)

Inventors: Andrew M. Rollins (Cleveland Heights, OH); Christine P. Fleming (Bronx, NY)
Assignee: Case Western Reserve University
A61B18/12A61B5/0066A61B5/6852A61B18/1492A61B18/02A61B18/20A61B2017/00243A61B2018/00351A61B2018/00702A61B2090/3735
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,883,901
App. No.
14/674,539
Granted
Feb 6, 2018
Kind
B2
Abstract

Systems, methods, and other embodiments associated with characterizing Radio Frequency Ablation (RFA) lesions using Optical Coherence Tomography (OCT) are described. One example method includes acquiring an OCT signal from a Region Of Interest (ROI) in an ablated material. The example method may also include determining whether a lesion was formed by the ablation by analyzing optical properties of the ROI as recorded in the OCT signal.

Claims (23)

1. A system comprising:

an ablation catheter comprising:

an ablation mechanism to ablate a region of interest (ROI) in a material; and

an optical coherence tomography (OCT) device to acquire an OCT signal from the ablated ROI; and

a computer apparatus coupled to the OCT device to determine a development stage of a lesion formed in the ablated ROI by analyzing an optical property of the ROI as recorded in the OCT signal.

2. The system of claim 1 , wherein the development stage is determined by the apparatus based on at least one of a size of the lesion and a length of the lesion.

3. The system of claim 1 , wherein the ablation mechanism employs at least one of Radio Frequency Ablation (RFA), High Intensity Focused Ultrasound (HIFU) ablation, laser ablation, and cryoablation.

4. The system of claim 1 , wherein the material is myocardial tissue.

5. The system of claim 1 , wherein the OCT device comprises an OCT detector.

6. The system of claim 1 , wherein the optical property comprises at least one of birefringence, anisotropy, absorption, light attenuation rate, backscattering, tissue scattering, mean intensity, and tissue heterogeneity.

7. The system of claim 1 , wherein the OCT device comprises an optical assembly coupled to an optical fiber and the ablation mechanism comprises a radio frequency ablation device that delivers radio frequency energy suitable to ablate the ROI.

8. The system of claim 7 , wherein the optical fiber and the radio frequency ablation device are enclosed within the ablation catheter.

9. The system of claim 8 , wherein the ablation catheter comprises a magnetic resonance imaging and radio frequency energy compatible catheter device.

10. The system of claim 7 , wherein the optical assembly is configured to rotate the optical fiber to provide a circular, forward-looking image of the ROI.

11. The system of claim 7 , wherein the optical assembly comprises a sheath tip, a GRIN lens, a Risley prism, and a ferrule, and

wherein the sheath tip is stationary with respect to the fiber optic cable.

12. A method comprising:

controlling a detector within an ablation catheter to acquire an optical coherence tomography OCT signal from a region of interest (ROI) in a material that has been or is being ablated by an ablation mechanism within the ablation catheter, wherein the ablation catheter is in direct contact with the material; and

controlling an apparatus coupled to the detector to determine a development stage of a lesion in the ROI due to the ablating as a function of analyzing an optical property of the lesion based on the OCT signal.

13. The method of claim 12 , wherein the detector performs a circular-scan imaging procedure.

14. The method of claim 12 , further comprising controlling the apparatus to stop the ablating upon determining that the lesion is a clinically relevant lesion or a borderline overtreatment lesion based on the optical property.

15. The method of claim 12 , wherein the optical property comprises at least one of birefringence, anisotropy, absorption, light attenuation rate, backscattering, tissue scattering, mean intensity, and tissue heterogeneity.

16. The method of claim 12 , wherein the material comprises myocardial tissue.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 12, 2015
From: ROLLINS, ANDREW M; FLEMING, CHRISTINE P.
To: CASE WESTERN RESERVE UNIVERSITY
Reel/Frame 037020/0186 →
Continuity (3)
Continuation 12844944 · Jul 28, 2010
Provisional Application 61230281 · Jul 31, 2009
Related Publication 20150202002A1 · Jul 23, 2015